TEMOPORFIN
Foscan (temoporfin) is a small molecule pharmaceutical. Temoporfin was first approved as Foscan on 2001-10-24. It has been approved in Europe to treat head and neck neoplasms and squamous cell neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| head and neck neoplasms | — | D006258 | — |
| squamous cell neoplasms | — | D018307 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 2 | 2 | — | — | 1 | 5 |
| Bile duct neoplasms | D001650 | — | — | — | 2 | — | — | — | 2 |
| Squamous cell carcinoma | D002294 | — | — | — | 1 | — | — | 1 | 2 |
| Head and neck neoplasms | D006258 | — | — | — | 2 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 1 | — | — | — | 1 |
| Klatskin tumor | D018285 | EFO_1001005 | — | — | 1 | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 1 | — | — | — | 1 |
| Nasopharyngeal carcinoma | D000077274 | — | — | — | 1 | — | — | — | 1 |
| Nasopharyngeal neoplasms | D009303 | — | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | — | — | — | — | 2 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Oropharyngeal neoplasms | D009959 | — | — | — | — | — | — | 1 | 1 |
| Tongue neoplasms | D014062 | EFO_0003871 | C02.9 | — | — | — | — | 1 | 1 |
| Verrucous carcinoma | D018289 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TEMOPORFIN |
| INN | temoporfin |
| Description | Temoporfin is a member of chlorins. It has a role as a photosensitizing agent. |
| Classification | Small molecule |
| Drug class | benzoporphyrin derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc2CC4)C=C3)c1 |
Identifiers
| PDB | — |
| CAS-ID | 122341-38-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL383675 |
| ChEBI ID | — |
| PubChem CID | 60751 |
| DrugBank | — |
| UNII ID | FU21S769PF (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,751 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use